The safety and efficacy of ezetimibe and simvastatin combination therapy in Korean patients with primary hypercholesterolemia.
- Author:
Jang Whan BAE
1
;
Hyo Soo KIM
;
Sang Chol LEE
;
Ki Hoon HAN
;
Eun Seok JEON
Author Information
1. Department of Internal Medicine, College of Medicine, Seoul National University, Seoul, Korea. hyosoo@snu.ac.kr
- Publication Type:Multicenter Study ; Randomized Controlled Trial ; Original Article
- Keywords:
Ezetimibe;
Simvastatin;
Hypercholesterolemia;
Cholesterol
- MeSH:
Absorption;
Apolipoprotein A-I;
Apolipoproteins;
Cholesterol;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Hypercholesterolemia*;
Korea;
Life Style;
Lipoprotein(a);
Lipoproteins;
Muscular Diseases;
Prevalence;
Simvastatin*;
Triglycerides;
Ezetimibe
- From:Korean Journal of Medicine
2005;68(5):487-497
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The prevalence of hypercholesterolemia in Korea is growing. In spite of the wide use of HMG-CoA reductase inhibitors (statins), some patients don't reach optimal cholesterol reduction and suffer hepatotoxicity or myopathy. Combination therapy of lipid lowering agents, which inhibits hepatic synthesis of cholesterol (i.e. simvastatin) and intestinal cholesterol absorption (i.e. ezetimibe), may achieve further reduction of serum cholesterol levels and less drug side effects. This study assessed the safety and efficacy of the combination therapy with ezetimibe and simvastatin in Korean patients with primary hypercholesterolemia. METHODS: This study was a randomized, double-blind, simvastatin controlled, multi-center trial. After 4 weeks of life style modification for cholesterol reduction, patients with a baseline low-density lipoprotein cholesterol (LDL-C) 145~250 mg/dL and triglyceride (TG)
